Salvador B. T.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase II Trial of Durvalumab, Olaparib, and Fulvestrant in ER-Positive, HER2-Negative Metastatic Breast Cancer with BRCA or HRR Gene Alterations
- Phase II Study on Maintenance Therapy with Trastuzumab and Pertuzumab Post-Trastuzumab Deruxtecan in HER2-Positive Unresectable Metastatic Breast Cancer
- Evaluation of Metformin for Hyperglycemia Prevention in HR+/HER2- PIK3CA-Mutated Advanced Breast Cancer Patients on Alpelisib and Endocrine Therapy
Data & Insights
Has run more than one trial at 74 of 274 partner sites.
Specializations
Breast Cancer Therapeutics
This investigator specializes in the treatment of HER2-positive breast cancer, with particular focus on advanced therapeutic approaches for patients with residual disease after standard treatments.
- Novel peptide-based immunotherapy
- Trastuzumab-based therapy optimization
- Post-neoadjuvant treatment strategies
The research extends to high-risk breast cancer patients requiring additional therapeutic interventions.
Hormone Receptor-Positive Disease
The investigator focuses on advancing treatment options for ER+/HER2- early breast cancer, particularly in the context of extended adjuvant therapy approaches.
- Extended endocrine therapy
- Novel therapeutic agents
- Recurrence prevention strategies
Expertise includes optimization of long-term endocrine-based treatments.
Advanced Breast Cancer Management
Research interests encompass treatment strategies for unresectable locally advanced and metastatic breast cancer, with emphasis on targeted therapeutic combinations.
- Targeted therapy sequencing
- Maintenance treatment approaches
- HER2-targeted combination therapies
The focus includes innovative approaches to maintenance therapy following induction treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.